Abstract
Screening for Latent Tuberculosis Infection (LTBI) is a critical prerequisite for children with Kawasaki Disease (KD) before they initiate immunosuppressive therapy. However, standard assays often yield "indeterminate" results in this population, delaying care. This study compares the performance of two Interferon-Gamma Release Assays (IGRAs)—the ELISA-based QFT-GIT and the ELISPOT-based X.DOT-TB—identifying high-dose intravenous immunoglobulin (IVIG) as a primary cause of test failure and recommending X.DOT-TB for more reliable clinical screening.
Introduction
Kawasaki Disease (KD) is an acute systemic vasculitis primarily affecting children under five. Management often requires aggressive immunosuppressive agents, such as corticosteroids or TNF-α inhibitors, which carry a significant risk of reactivating latent tuberculosis. Consequently, accurate LTBI screening is essential. While the IGRA is the preferred screening tool, clinicians frequently encounter indeterminate results in KD patients. This study investigates the mechanisms behind these failures and evaluates which technology offers better diagnostic stability.
Methodology
Researchers conducted a retrospective analysis of 1,327 children with KD at Beijing Children’s Hospital. The study compared two distinct IGRA technologies:
- QFT-GIT (QuantiFERON-TB Gold In-Tube): An ELISA-based assay using whole blood to measure the total concentration of interferon-gamma (IFN-γ) released after stimulation.
- X.DOT-TB: An ELISPOT-based assay that uses isolated and washed Peripheral Blood Mononuclear Cells (PBMCs) to count individual T-cells secreting IFN-γ.
Additionally, in vitro experiments were performed to assess how Intravenous Immunoglobulin (IVIG)—the standard first-line treatment for KD—impacts IFN-γ release.
Comparative Performance and Indeterminate Rates
The study revealed a stark contrast in reliability. QFT-GIT produced indeterminate results in 68.2% of cases, rendering it largely ineffective for this patient group. In contrast, X.DOT-TB maintained a significantly lower failure rate of only 6.1%.
Age was also a significant factor. Children under five years old exhibited higher frequencies of indeterminate results across both tests, likely due to immature immune responses. However, X.DOT-TB consistently outperformed QFT-GIT across all pediatric brackets, as shown in the age-group analysis.
The Impact of IVIG Interference
The high failure rate of QFT-GIT is primarily attributed to the inhibitory effects of high-dose IVIG. Experimental data demonstrated that high-dose IVIG concentrations (15 mg/ml) inhibit IFN-γ release by over 90%.
Because QFT-GIT utilizes whole blood, the IVIG remains present during the assay, suppressing the diagnostic signal the test is designed to measure. X.DOT-TB circumvents this issue through its "wash-out" process: isolating PBMCs and washing them removes the plasma containing the inhibitory IVIG before the cells are stimulated, allowing for a clear diagnostic signal.
Clinical Considerations and Conclusion
Beyond IVIG therapy, clinical factors such as hypoproteinemia, shock, and critical illness were identified as significant risk factors for indeterminate IGRA results. While the exact biological mechanism of how low albumin levels interfere with T-cell responses requires further study, the immediate clinical implication is clear.
For children with Kawasaki Disease, particularly those receiving IVIG therapy, X.DOT-TB is the superior screening method for LTBI. Its ability to provide valid results where whole-blood assays fail ensures that critical immunosuppressive treatments are not delayed by diagnostic uncertainty.
Summary updated